VIBRAMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibramycin, and when can generic versions of Vibramycin launch?
Vibramycin is a drug marketed by Pfizer and is included in four NDAs.
The generic ingredient in VIBRAMYCIN is doxycycline calcium. There are twenty-eight drug master file entries for this compound. Additional details are available on the doxycycline calcium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIBRAMYCIN?
- What are the global sales for VIBRAMYCIN?
- What is Average Wholesale Price for VIBRAMYCIN?
Summary for VIBRAMYCIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 177 |
| Clinical Trials: | 22 |
| Patent Applications: | 4,423 |
| Drug Prices: | Drug price information for VIBRAMYCIN |
| Drug Sales Revenues: | Drug sales revenues for VIBRAMYCIN |
| DailyMed Link: | VIBRAMYCIN at DailyMed |
See drug prices for VIBRAMYCIN
Recent Clinical Trials for VIBRAMYCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mahidol Oxford Tropical Medicine Research Unit | Phase 2/Phase 3 |
| Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | Phase 2/Phase 3 |
| University of Iowa | Phase 4 |
US Patents and Regulatory Information for VIBRAMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pfizer | VIBRAMYCIN | doxycycline hyclate | INJECTABLE;INJECTION | 050442-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pfizer | VIBRAMYCIN | doxycycline hyclate | CAPSULE;ORAL | 050007-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Pfizer | VIBRAMYCIN | doxycycline | FOR SUSPENSION;ORAL | 050006-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pfizer | VIBRAMYCIN | doxycycline calcium | SUSPENSION;ORAL | 050480-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pfizer | VIBRAMYCIN | doxycycline hyclate | INJECTABLE;INJECTION | 050442-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for VIBRAMYCIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Limited | Doxirobe | Doxycycline | EMEA/V/C/000044 Treatment of periodontal disease in dogs.Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy. |
Withdrawn | no | no | no | 1999-09-16 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
